Literature DB >> 20833347

Simulation of colorectal cancer screening: what we do and do not know and does it matter.

Marjolein van Ballegooijen1, Rob Boer, Ann G Zauber.   

Abstract

Simulation modelling is increasingly used to inform decision-making on screening, including colorectal cancer screening strategies. The strength of simulation is its ability to handle complexity and to identify the implications of uncertainty in a formal, documented, reproducible and consistent way. Important specific uncertainties concerning colorectal cancer screening are the dwell time of adenomas and the associated sensitivity of the various tests. Concerning these issues, for distal colorectal neoplasia, knowledge has been greatly increased by the recent availability of the once only sigmoidoscopy randomised trial results. Other uncertainties concern the quality of life effects of screening, diagnostic and surveillance colonoscopies, and the true total costs of the various screening modalities in a routine high throughput efficient setting. A limitation of simulation of screening is that complexity leads to lack of insight and understanding into the models used, and therefore a lack of sound criticism, acceptance and use amongst decision makers. Modellers are currently focussing on ways to make models and the implications of assumptions more transparent. Thus it is important to further develop the quality and acceptability of simulation, especially that for colorectal cancer screening.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20833347      PMCID: PMC4197829          DOI: 10.1016/j.bpg.2010.07.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  25 in total

1.  Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults.

Authors:  Perry J Pickhardt; J Richard Choi; Inku Hwang; James A Butler; Michael L Puckett; Hans A Hildebrandt; Roy K Wong; Pamela A Nugent; Pauline A Mysliwiec; William R Schindler
Journal:  N Engl J Med       Date:  2003-12-01       Impact factor: 91.245

2.  The price tag on progress--chemotherapy for colorectal cancer.

Authors:  Deborah Schrag
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

3.  Prospective blinded trial of the colonoscopic miss-rate of large colorectal polyps.

Authors:  L J Hixson; M B Fennerty; R E Sampliner; H S Garewal
Journal:  Gastrointest Endosc       Date:  1991 Mar-Apr       Impact factor: 9.427

4.  Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis.

Authors:  Iris Lansdorp-Vogelaar; Karen M Kuntz; Amy B Knudsen; Janneke A Wilschut; Ann G Zauber; Marjolein van Ballegooijen
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

5.  Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies.

Authors:  D K Rex; C S Cutler; G T Lemmel; E Y Rahmani; D W Clark; D J Helper; G A Lehman; D G Mark
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

6.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

7.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

8.  National Polyp Study data: evidence for regression of adenomas.

Authors:  Franka Loeve; Rob Boer; Ann G Zauber; Marjolein Van Ballegooijen; Gerrit J Van Oortmarssen; Sidney J Winawer; J Dik F Habbema
Journal:  Int J Cancer       Date:  2004-09-10       Impact factor: 7.396

9.  Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE.

Authors:  Nereo Segnan; Carlo Senore; Bruno Andreoni; Hugo Aste; Luigina Bonelli; Cristiano Crosta; Roberto Ferraris; Stefano Gasperoni; Angelo Penna; Mauro Risio; Francesco Paolo Rossini; Stefania Sciallero; Marco Zappa; Wendy S Atkin
Journal:  J Natl Cancer Inst       Date:  2002-12-04       Impact factor: 13.506

10.  Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer.

Authors:  G Castiglione; M Zappa; G Grazzini; A Mazzotta; M Biagini; P Salvadori; S Ciatto
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

View more
  2 in total

1.  The BSG mission possible: the potential and challenges of setting up a colorectal cancer screening programme in Iraq.

Authors:  Laith Alrubaiy; Ali K Q Al-Rubaye
Journal:  Frontline Gastroenterol       Date:  2022-06-08

2.  The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium.

Authors:  Jasmin A Tiro; Aruna Kamineni; Theodore R Levin; Yingye Zheng; Joanne S Schottinger; Carolyn M Rutter; Douglas A Corley; Celette S Skinner; Jessica Chubak; Chyke A Doubeni; Ethan A Halm; Samir Gupta; Karen J Wernli; Carrie Klabunde
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-10       Impact factor: 4.254

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.